A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
PharmacoEconomics, 2009-01, Vol.27 (10), p.829-846 [Peer Reviewed Journal]Adis Data Information BV 2009 ;2015 INIST-CNRS ;Copyright Wolters Kluwer Health Adis International Oct 2009 ;ISSN: 1170-7690 ;EISSN: 1179-2027 ;DOI: 10.2165/11313800-000000000-00000 ;PMID: 19803538
Full text available